AEON Biopharma Files 8-K for Amendments and Financials
Ticker: AEON · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1837607
Sentiment: neutral
Topics: corporate-update, financials
TL;DR
AEON Biopharma filed an 8-K on 12/18/24 for corporate changes and financials.
AI Summary
AEON Biopharma, Inc. filed an 8-K on December 18, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as Priveterra Acquisition Corp. until December 22, 2020, is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This filing indicates corporate changes and the submission of financial information, which are crucial for investors to assess the company's current status and financial health.
Risk Assessment
Risk Level: low — This is a routine filing for corporate updates and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- December 18, 2024 (date) — Date of earliest event reported
- December 22, 2020 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
- Irvine, CA (location) — Principal executive offices
FAQ
What specific amendments were made to AEON Biopharma's articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text.
What is the purpose of filing financial statements with this 8-K?
The filing states that financial statements are being included as part of the report, typically to disclose financial performance or position.
When did AEON Biopharma officially change its name from Priveterra Acquisition Corp.?
The company's name was changed from Priveterra Acquisition Corp. on December 22, 2020.
Where are AEON Biopharma's principal executive offices located?
AEON Biopharma's principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What is the SEC file number for AEON Biopharma?
The SEC file number for AEON Biopharma, Inc. is 001-40021.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-12-20 16:05:24
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri
Filing Documents
- tm2431750d1_8k.htm (8-K) — 28KB
- tm2431750d1_ex3-1.htm (EX-3.1) — 6KB
- 0001104659-24-130805.txt ( ) — 209KB
- aeon-20241218.xsd (EX-101.SCH) — 3KB
- aeon-20241218_lab.xml (EX-101.LAB) — 33KB
- aeon-20241218_pre.xml (EX-101.PRE) — 22KB
- tm2431750d1_8k_htm.xml (XML) — 4KB
03 Amendment to Articles of Incorporation
Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 18, 2024, Aeon Biopharma, Inc. (the "Company") amended its amended and restated bylaws (the "Bylaws") to change the quorum requirement for shareholder meetings from a majority to 33.34% of the voting power of the Company's outstanding shares entitled to vote at a meeting. A copy of the Certificate of Amendment of the Bylaws of the Company is filed herein as Exhibit 3.1 and is incorporated herein by reference.
01. Financial Statement and Exhibits
Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Bylaws dated December 18, 2024 104 Cover Page Interactive Data File (formatted in Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: December 20, 2024 By: /s/ Marc Forth Marc Forth Chief Executive Officer